Mason Street Advisors’s Impax Laboratories, Inc. IPXL Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2018
Q2 | – | Sell |
-20,511
| Closed | -$399K | – | 1535 |
|
|
2018
Q1 | $399K | Buy |
20,511
+1,235
| +6% | +$24.2K | 0.01% | 1118 |
|
|
2017
Q4 | $321K | Buy |
19,276
+455
| +2% | +$8.34K | 0.01% | 1183 |
|
|
2017
Q3 | $382K | Buy |
18,821
+646
| +4% | +$12.3K | 0.01% | 1101 |
|
|
2017
Q2 | $293K | Buy |
18,175
+930
| +5% | +$13.7K | 0.01% | 1168 |
|
|
2017
Q1 | $218K | Buy |
17,245
+1,101
| +7% | +$13.3K | 0.01% | 1249 |
|
|
2016
Q4 | $214K | Buy |
16,144
+939
| +6% | +$16.1K | 0.01% | 1241 |
|
|
2016
Q3 | $360K | Buy |
15,205
+1,641
| +12% | +$44.1K | 0.01% | 1026 |
|
|
2016
Q2 | $391K | Buy |
13,564
+1,432
| +12% | +$46.7K | 0.01% | 973 |
|
|
2016
Q1 | $388K | Buy |
12,132
+1,449
| +14% | +$50.9K | 0.01% | 946 |
|
|
2015
Q4 | $457K | Buy |
10,683
+670
| +7% | +$26.8K | 0.01% | 905 |
|
|
2015
Q3 | $353K | Buy |
10,013
+802
| +9% | +$36.1K | 0.01% | 939 |
|
|
2015
Q2 | $423K | Buy |
9,211
+403
| +5% | +$19.1K | 0.01% | 922 |
|
|
2015
Q1 | $413K | Buy |
8,808
+284
| +3% | +$11.3K | 0.01% | 923 |
|
|
2014
Q4 | $270K | Buy |
8,524
+319
| +4% | +$9.34K | ﹤0.01% | 1415 |
|
|
2014
Q3 | $195K | Buy |
8,205
+15
| +0.2% | +$384 | ﹤0.01% | 1485 |
|
|
2014
Q2 | $246K | Buy |
8,190
+269
| +3% | +$7.26K | ﹤0.01% | 1430 |
|
|
2014
Q1 | $209K | Sell |
7,921
-2,368
| -23% | -$59.2K | ﹤0.01% | 1438 |
|
|
2013
Q4 | $259K | Buy |
10,289
+873
| +9% | +$19.5K | ﹤0.01% | 1448 |
|
|
2013
Q3 | $193K | Buy |
9,416
+401
| +4% | +$8.28K | ﹤0.01% | 1323 |
|
|
2013
Q2 | $180K | Buy |
+9,015
| New | +$160K | ﹤0.01% | 1254 |
|
Mason Street Advisors's IPXL Position: Q2 2018 in Review
Mason Street Advisors sold out of Impax Laboratories, Inc. (IPXL) in Q2 2018, closing a stake of 20,511 shares — an estimated $399K sold.
Mason Street Advisors first reported a position in IPXL in Q2 2013 and held it in 20 quarters. The position peaked at $457K in Q4 2015. 1 fund tracked by Wall St. Rank holds IPXL as of Q2 2018.
- Mason Street Advisors reported no remaining Impax Laboratories, Inc. position as of Q2 2018 after selling out during the quarter.
- Mason Street Advisors sold 20,511 Impax Laboratories, Inc. shares in Q2 2018, an estimated $399K.
- Mason Street Advisors first reported a position in Impax Laboratories, Inc. in Q2 2013 and held it in 20 quarters.
- Mason Street Advisors's Impax Laboratories, Inc. position peaked at $457K in Q4 2015.
- 1 fund tracked by Wall St. Rank held Impax Laboratories, Inc. as of Q2 2018.
Based on Mason Street Advisors's 13F filing for Q2 2018, filed 14 Aug 2018.